NASDAQ:MGX Metagenomi Q3 2025 Earnings Report $1.42 +0.02 (+1.06%) As of 11:30 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Metagenomi EPS ResultsActual EPS-$0.55Consensus EPS -$0.60Beat/MissBeat by +$0.05One Year Ago EPSN/AMetagenomi Revenue ResultsActual Revenue$8.66 millionExpected Revenue$7.82 millionBeat/MissBeat by +$836.00 thousandYoY Revenue GrowthN/AMetagenomi Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time7:00AM ETUpcoming EarningsMetagenomi's Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Metagenomi Earnings HeadlinesMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing ...April 16, 2026 | markets.businessinsider.comMetagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyApril 16, 2026 | globenewswire.comElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.May 6 at 1:00 AM | InvestorPlace (Ad)Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?April 13, 2026 | prnewswire.comMetagenomi Therapeutics: Q4 Earnings SnapshotMarch 5, 2026 | sfgate.comMetagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsMarch 5, 2026 | globenewswire.comSee More Metagenomi Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Metagenomi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metagenomi and other key companies, straight to your email. Email Address About MetagenomiMetagenomi (NASDAQ:MGX) (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives. Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors. The company works with manufacturers to enhance biofuel production, create greener chemical intermediates and develop more effective formulations for detergents, textiles and crop protection. In the biopharmaceutical realm, Metagenomi’s novel genome-editing components have the potential to drive next-generation gene therapies and precision medicine approaches by enabling targeted modifications in living cells. Founded in 2019 and headquartered in South San Francisco, Metagenomi has rapidly expanded through strategic collaborations and research partnerships with industry leaders and academic institutions. The company’s management team combines deep expertise in genomics, computational biology and industrial biotechnology, positioning Metagenomi to serve global markets and address growing demand for sustainable, biologically derived solutions. As it advances its pipeline programs and broadens its partner network, Metagenomi continues to pursue breakthrough innovations that bridge metagenomics data with real-world manufacturing needs.View Metagenomi ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Years in the Making, AMD’s Upside Movement Has Just BegunPinterest Pins a Profit Play To Its Mood BoardJust How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating SystemGrab Holdings Faces Hurdles, But Upside Potential Is Hard to IgnorePalantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026 Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
